Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Best Buy Co Inc (BBY) vs BioNTech SE - ADR (BNTX) Price & Performance

Best Buy Co IncTrade
BioNTech SE - ADRTrade

Price performance (Past 24H)

Key statistics

Best Buy Co Inc vs BioNTech SE - ADR — how do they compare? Best Buy Co Inc trades at $83.03 (market cap $17.55B), while BioNTech SE - ADR trades at $93.06 (market cap $23.31B). The key difference: BioNTech SE - ADR is the larger of the two by market cap, and Best Buy Co Inc pays a 4.61% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.

BBYBNTX
Market Cap
$17.55B$23.31B
Sector
Consumer CyclicalHealth
52-Week High
$90.17$119.34
52-Week Low
$55.52$83.89
Enterprise Value
$19.93B$6.60B
Dividend Yield
4.61%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Best Buy Co Inc

BBY trades at $83.24, up 0.98% on the day, near the consensus price target of $84.31. The stock shows a neutral technical signal with bullish moving averages. Recent earnings have consistently beaten estimates, and the company maintains solid profitability with a 39.1% ROE. Leadership changes, including a new CFO, and store format tests aim to drive future growth amid declining revenues.

The outlook is mixed: strong cash flow improvement and shareholder returns via dividends support upside, but revenue declines and competitive pressures pose risks. Analysts are cautious with a 'Hold' majority. Investors should weigh valuation attractiveness against execution challenges in a tough retail environment.

BioNTech SE - ADR

BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.

The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.

Returns comparison

Trailing returns across standard periods

About Best Buy Co Inc

With $51.8 billion in fiscal 2022 sales, Best Buy is the largest pure-play consumer electronics retailer in the U.S., with roughly 10.6% share of the aggregate market and north of 40% share of offline sales, per our calculations, CTA industry, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the COVID-19 pandemic, have seen the U.S. e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.

Read more on BBY

About BioNTech SE - ADR

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.

Read more on BNTX